NCT00511524View on ClinicalTrials.gov

An Imaging Study to Investigate the Distribution of GW842166X in the Brain.

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 26, 2007

Primary Completion Date

July 4, 2007

Study Completion Date

July 4, 2007

Conditions
Pain, Inflammatory
Interventions
DRUG

GW842166X

GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.

DRUG

[carbonyl-^11C]GW842166

\[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.

Trial Locations (1)

SE-753 23

GSK Investigational Site, Uppsala

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00511524 - An Imaging Study to Investigate the Distribution of GW842166X in the Brain. | Biotech Hunter | Biotech Hunter